So even though it's a time-limited pilot for now, I would not want individuals to try to take advantage of the highest doses possible and achieve a rapid weight loss
Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
If your employer's plan excludes anti-obesity medications entirely (common in self-insured plans), your options are: the cash-pay manufacturer programs described above, asking your HR department whether the exclusion can be reconsidered (especially if your employer is large enough to modify the plan), or using the medication under a different indication (for example, Ozempic for type 2 diabetes, if applicable)
Zepbound , once-weekly injection for chronic weight management (FDA-approved 2023), clinical trials (SURMOUNT program) demonstrated up to 22.5% body weight loss, the highest of any approved anti-obesity medication
Between months 4-6, sustained weight loss continues at a steady pace